Cargando…
Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections
Oral administration of specific antibodies is an attractive approach to establish protective immunity against gastrointestinal pathogens in humans and animals. The increasing number of antibiotic-resistant bacteria emphasize the need to find alternatives to antibiotics. Immunotherapy can also be use...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Humana Press
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090601/ https://www.ncbi.nlm.nih.gov/pubmed/10803878 http://dx.doi.org/10.1385/IR:21:1:1 |
_version_ | 1783509939296141312 |
---|---|
author | Carlander, David Kollberg, Hans Wejåker, Per-Erik Larsson, Anders |
author_facet | Carlander, David Kollberg, Hans Wejåker, Per-Erik Larsson, Anders |
author_sort | Carlander, David |
collection | PubMed |
description | Oral administration of specific antibodies is an attractive approach to establish protective immunity against gastrointestinal pathogens in humans and animals. The increasing number of antibiotic-resistant bacteria emphasize the need to find alternatives to antibiotics. Immunotherapy can also be used against pathogens that are difficult to treat with traditional antibiotics. Laying hens are very good producers of specific antibodies. After immunization, the specific antibodies are transported to the egg yolk from which the antibodies then can be purified. A laying hen produces more than 20 g of yolk antibodies (IgY) per year. These antibodies also have biochemical properties that make them attractive for peroral immunotherapy: They neither activate mammalian complement nor interact with mammalian Fc receptors that could mediate inflammatory response in the gastrointestinal tract. Eggs are also normal dietary components and thus there is practically no risk of toxic side effects of IgY. Yolk antibodies have been shown in several studies to prevent bacterial and viral infections. |
format | Online Article Text |
id | pubmed-7090601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Humana Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70906012020-03-24 Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections Carlander, David Kollberg, Hans Wejåker, Per-Erik Larsson, Anders Immunol Res Article Oral administration of specific antibodies is an attractive approach to establish protective immunity against gastrointestinal pathogens in humans and animals. The increasing number of antibiotic-resistant bacteria emphasize the need to find alternatives to antibiotics. Immunotherapy can also be used against pathogens that are difficult to treat with traditional antibiotics. Laying hens are very good producers of specific antibodies. After immunization, the specific antibodies are transported to the egg yolk from which the antibodies then can be purified. A laying hen produces more than 20 g of yolk antibodies (IgY) per year. These antibodies also have biochemical properties that make them attractive for peroral immunotherapy: They neither activate mammalian complement nor interact with mammalian Fc receptors that could mediate inflammatory response in the gastrointestinal tract. Eggs are also normal dietary components and thus there is practically no risk of toxic side effects of IgY. Yolk antibodies have been shown in several studies to prevent bacterial and viral infections. Humana Press 2000 /pmc/articles/PMC7090601/ /pubmed/10803878 http://dx.doi.org/10.1385/IR:21:1:1 Text en © Humana Press Inc 2000 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Carlander, David Kollberg, Hans Wejåker, Per-Erik Larsson, Anders Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title | Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title_full | Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title_fullStr | Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title_full_unstemmed | Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title_short | Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
title_sort | peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090601/ https://www.ncbi.nlm.nih.gov/pubmed/10803878 http://dx.doi.org/10.1385/IR:21:1:1 |
work_keys_str_mv | AT carlanderdavid peroralimmunotheraphywithyolkantibodiesforthepreventionandtreatmentofentericinfections AT kollberghans peroralimmunotheraphywithyolkantibodiesforthepreventionandtreatmentofentericinfections AT wejakerpererik peroralimmunotheraphywithyolkantibodiesforthepreventionandtreatmentofentericinfections AT larssonanders peroralimmunotheraphywithyolkantibodiesforthepreventionandtreatmentofentericinfections |